Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 2

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × naquotinib × Clear all
NCT02674555 2017-07-28

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Astellas Pharma Inc

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT03042013 2017-07-11

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Astellas Pharma Inc

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡